Supporting Information

Enantioselective synthesis of 1,2,5,6-tetrahydropyridines (THPs) via proline-

catalyzed direct Mannich-cyclization/domino oxidation-reduction sequence:

Application for medicinally important N-heterocycles

Panduga Ramaraju, ^a Nisar A. Mir, ^a Deepika Singh,^b and Indresh Kumar,^{*a}

^a Department of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, Rajasthan, India E-mail: indresh.chemistry@gmail.com, indresh.kumar@bits-pilani.ac.in

^b Instrumentation Division, IIIM-CSIR Laboratory, Jammu 180 001, Jammu and Kashmir, India

Table of Contents:

General Experimental Methods	S2
General procedure for THPs synthesis	S2
Detailed mechanism for multicomponent reaction	S3
Analytical data of synthesized compounds	S4
Characterization data: ¹ H and ¹³ C NMR copies and HPLC Data for compounds	S18

General Experimental Methods:

All reactions under standard conditions were monitored by thin-layer chromatography (TLC) through SiO₂ gel F-254 plates. All reagents were of analytical grade and used without further purification. ¹H and ¹³C NMR spectra were recorded in CDCl₃ solution and spectral data were reported in ppm relative to tetramethylsilane (TMS) as an internal standard. High-resolution mass spectra were recorded using the quadruple electrospray ionization (ESI) technique. HPLC was performed on Water-2998-instrument with CHIRALPAK-IA and IB columns using hexane/2-propanol.

General procedure for THPs 5:

To a stirred solution of aryl aldehyde 2 (0.3 mmol) in DMSO (3.0 mL) at rt was added *p*-anisidine 3 (0.3 mmol) and stirred for additional 3 hr at the same temperature. To this mixture, was added glutaraldehyde 4 (25 % sol. in water, 0.360 mL, 0.9 mmol), and L-proline 1 (6.9 mg, 0.06 mmol) and taken to 10 °C. This reaction mixture was further stirred at the same temperature until the in situ generated imine was consumed completely as monitored by TLC. IBX (2-Iodoxybenzoic acid) (1.2 equiv, 0.36 mmol) was added into the same flask and further heated to 40 °C for 4 hrs. This reaction mixture was then cooled to 0 °C and Methanol (3.0 mL) was added followed by NaBH₄ (in excess and portion wise) along with CH₃CO₂H (200 mol %) until the dark red color of the solution turned into pale reddish yellow. The reaction was quenched slowly with saturated NaHCO₃ (5.0 mL, 20% sol.) and stirred with ethyl acetate (10 mL) for 10 min. at rt and organic layer was separated out. The aqueous layer was further extracted with ethyl acetate (10 mL) and the combined organic extracts were washed with brine solution, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure after filtration. Purification was performed by a silica gel column and eluted with hexane/EtOAc to give product **5** (58-80% yields). The enantiomeric ratios (er) of the products were determined by stationary chiral phase HPLC analysis.



Scheme 1: Detailed plausible mechanism for the multicomponent asymmetric synthesis of 1,2,5,6-THPs

Analytical data of the synthesized compounds

(*R*)-(1-(4-Methoxyphenyl)-2-(2-nitrophenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5a):



Yellow viscous oil, (64 mg, 63% yield), ¹H NMR (400 MHz, CDCl₃) δ 1.77– 1.79 (bs, 1H), 2.18–2.23 (m, 1H), 2.25-2.32 (m, 1H), 3.00–3.07 (m, 1H), 3.15– 3.19 (m, 1H), 3.73 (s, 3H), 4.06 (s, 2H), 5.80 (s, 1H), 6.16 (t, J = 4.2 Hz, 1H),6.72 (d, J = 9.1 Hz, 2H), 6.84 (d, J = 9.1 Hz, 2H), 7.32–7.36 (m, 1H), 7.50–7.51 (m, 2H), 7.63 (d, J = 8.5 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 23.70, 44.50, 55.35, 55.57, 64.91,

114.20 (2C), 121.40 (2C), 124.16, 125.61, 128.02, 130.13, 131.66, 135.19, 136.73, 143.78, 150.57, 154.65; IR (KBr)/cm⁻¹ 3448, 2924, 2854, 1520, 1466, 1350, 1242, 1180, 1034; HRMS (ESI): Calcd for $C_{19}H_{20}N_2O_4$ (MH⁺) 341.1501; Found: 341.1504. $[\alpha]_D^{25} = -81.4$ (*c* 0.1, CH₂Cl₂). HPLC analysis: 97:3 er [Daicel Chiralpak-IB, n-hexane/2-propanol = 94/06), flow rate (0.8 mL/min), t (minor) = 15.224 min, t (major) = 22.808 min].

(*R*)-(1-(4-Methoxyphenyl)-2-(3-nitrophenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5b):



Pale yellow viscous liquid, (75 mg, 74% yield), ¹H NMR (400 MHz, $CDCl_3$) δ 2.33–2.47 (m, 2H), 3.10–3.22 (m, 2H), 3.73 (s, 3H), 3.86 (d, J = 12.8 Hz, 1H), 4.01 (d, J = 12.8 Hz, 1H), 5.20 (s, 1H), 6.16 (t, J = 3.1 Hz, 1H), 6.75 (d, J = 9.1 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 7.37 (t, J = 7.9 Hz,

1H), 7.45 (d, J = 7.9 Hz, 1H), 8.02–8.08 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.68, 43.00, 55.40, 61.64, 64.78, 114.24 (2C), 121.24 (2C), 122.41, 123.23, 125.30, 128.76, 135.14, 136.77, 141.61, 143.76, 147.90, 154.34; IR (KBr)/cm⁻¹ 3418, 2924, 2847, 1605, 1520, 1458, 1342, 1250, 1188, 1034; HRMS (ESI): Calcd for $C_{19}H_{20}N_2O_4$ (MH⁺) 341.1501; Found: 341.1508. $[\alpha]_D^{25} = -$ 173 (c 0.5, CH₂Cl₂). HPLC analysis: 94:6 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), t (minor) = 29.538 min, t (major) = 33.207 min].

(*R*)-(1-(4-Methoxyphenyl)-2-(4-nitrophenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5c):



Yellowish viscous oil, (82 mg, 80% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.32–2.47 (m, 2H), 3.11–3.22 (m, 2H), 3.74 (s, 3H), 3.85 (d, J = 12.7 Hz, 1H), 3.99 (d, J = 12.8 Hz, 1H), 5.18 (s, 1H), 6.14 (t, J = 3.2 Hz, 1H), 6.75(d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 7.31 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.79, 42.96, 55.32, 61.74, 66.59, 114.15 (2C), 121.20 (2C), 122.98 (2C), 124.84, 129.48 (2C), 136.81, 143.68, 146.82, 147.80, 154.28; IR (KBr)/cm⁻¹ 3446, 2925, 2854,1522, 1468, 1350, 1241, 1180, 1034; HRMS (ESI Calcd for C₁₉H₂₀N₂O₄ (MH⁺) 341.1501; Found: 341.1495. [α]_D²⁵ = – 198 (*c* 1.0, CH₂Cl₂). HPLC analysis: 97:3 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 80/20), flow rate (1.0 mL/min), *t* (minor) = 17.932 min, *t* (major) = 22.037 min].

(S)-(2-(2-Fluorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5d):



Reddish viscous oil, (57 mg, 61% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.17–2.22 (m, 1H), 2.27–2.32 (m, 1H), 3.28–3.31 (m, 2H), 3.74 (s, 3H), 3.94 (s, 2H), 5.48 (s, 1H), 6.11 (t, *J* = 3.9 Hz, 1H), 6.77 (d, *J* = 8.9 Hz, 2H), 7.02 (d, *J* = 9.0 Hz, 2H), 7.17–7.22 (m, 2H), 7.32–7.34 (m, 1H) 7.39–7.41(m, 1H); ¹³C NMR

(75 MHz, CDCl₃) δ 23.38, 44.79, 55.37, 57.34, 64.71, 114.08 (2C), 120.67 (2C), 124.84, 126.43, 128.51, 129.81, 129.96, 135.32, 137.64, 138.39, 144.27, 153.89; IR (KBr)/cm⁻¹ 3140, 2916, 2850,1660, 1508, 1246, 1178; HRMS (ESI): Calcd for C₁₉H₂₀FNO₂ (MH⁺) 314.1556; Found: 314.1559. [α]_D²⁵ = - 46.1 (*c* 0.8, CH₂Cl₂). HPLC analysis: 98:2 er [Daicel Chiralpak-IB, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 11.835 min, *t* (major) = 14.871 min].

(R)-(2-(3-Fluorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5e)



Yellow viscous liquid, (62 mg, 66% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.26–2.31 (m, 1H), 2.39–2.47 (m, 1H), 3.18–3.21 (m, 2H), 3.74 (s, 3H), 3.91 (d, *J* = 12.4 Hz, 1H), 3.99 (d, *J* = 12.7 Hz, 1H), 5.08 (s, 1H), 6.10 (t, *J* = 4.3 Hz, 1H), 6.76 (d, *J* = 9.1 Hz, 2H), 6.86 (d, *J* = 9.2 Hz, 3H), 6.90–6.92 (m,

2H), 7.14–7.20 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 24.62, 42.63, 55.44, 61.87, 64.97, 114.15 (2C), 114.33, 115.41, 115.62, 120.88 (2C), 124.39, 124.67, 129.27, 129.35, 137.59, 144.24, 153.99; IR (KBr)/cm⁻¹ 3420, 2924, 2848, 1655, 1589, 1247, 1170; HRMS (ESI Calcd for C₁₉H₂₀FNO₂ (MH⁺) 314.1556; Found: 314.1562. [α]_D²⁵ = – 41.3 (*c* 0.6, CH₂Cl₂). HPLC analysis: 81:19 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 17.480 min, *t* (major) = 20.078 min].

(*R*)-(2-(4-Fluorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5f):



Yellowish viscous liquid, (64 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.25–2.26 (m, 1H), 2.39–2.47 (m, 1H), 3.14–3.17 (m, 2H), 3.74 (s, 3H), 3.93 (m, 2H), 5.07 (s, 1H), 6.09 (t, *J* = 4.4 Hz, 1H), 6.75 (d, *J* = 9.2 Hz, 2H), 6.84 (d, *J* = 9.1 Hz, 2H), 6.89 (t, *J* = 8.7 Hz, 2H), 7.07 (m, 2H); ¹³C NMR

(75 MHz, CDCl₃) δ 24.76, 42.35, 55.43, 61.80, 65.02, 114.10 (2C), 114.62, 114.83, 121.16 (2C), 124.14, 130.35, 130.43, 134.74, 137.93, 144.31, 154.04, 160.83; IR (KBr)/cm⁻¹ 3426, 2924, 2854, 1643, 1597, 1512, 1242, 1034, 825, 725; HRMS (ESI): Calcd for C₁₉H₂₀FNO₂ (MH⁺) 314.1556; Found: 314.1549. [α]_D²⁵ = -101 (*c* 0.2, CH₂Cl₂). HPLC analysis: 83:17 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 18.826 min, *t* (major) = 20.510 min].

(S)-(2-(2-Chlorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5g):



Dark red viscous liquid, (64 mg, 65% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.16–2.23 (m, 1H), 2.25–2.34 (m, 1H), 3.28–3.31 (m, 2H), 3.74 (s, 3H), 3.93 (s, 2H), 5.48 (s, 1H), 6.11 (t, J = 3.8 Hz, 1H), 6.77 (d, J = 9.1 Hz, 2H), 7.02 (d, J = 9.0 Hz, 2H), 7.15–7.22 (m, 2H), 7.32–7.34 (m, 1H), 7.37–7.41 (m, 1H); ¹³C

NMR (75 MHz, CDCl₃) δ 23.35, 44.76, 55.38, 57.30, 64.75, 114.07 (C), 120.64 (2C), 124.90, 126.44, 128.53, 129.83, 129.96, 153.33, 137.62, 138.38, 144.25, 153.87; IR (KBr)/cm⁻¹ 3418, 2924, 2862, 1659, 1512, 1458, 1250, 1188, 1095, 1034; HRMS (ESI): Calcd for C₁₉H₂₀ClNO₂ (MH⁺) 330.1261; Found : 330.1255. [α]_D²⁵ = - 76.6 (*c* 0.3, CH₂Cl₂). HPLC analysis: 97:3 er [Daicel Chiralpak-IB, *n*-hexane/2-propanol = 90/10), flow rate (0.6 mL/min), *t* (minor) = 8.278 min, *t* (major) = 11.601 min].

(*R*)-(2-(3-Chlorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5h):



Pale yellow liquid, (67 mg, 68% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.19 (bs, 1H), 2.25–2.30 (m, 1H), 2.40–2.46 (m, 1H), 3.17–3.20 (m, 2H), 3.78 (s, 3H), 3. 89 (d, J = 12.8 Hz, 1H), 3.98 (d, J = 12.8 Hz, 1H), 5.06 (s, 1H), 6.09

(t, J = 3.2 Hz, 1H), 6.76 (d, J = 9.1 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 6.98–7.01 (m, 1H), 7.08– 7.13 (m, 1H), 7.15–7.19 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.47, 42.47, 55.42, 6180, 64.76, 114.14 (2C), 120.87 (2C), 124.36, 127.25, 127.46, 128.64, 129.12, 133.79, 137.33, 141.36, 144.03, 154.01; IR (KBr)/cm⁻¹ 3464, 2924, 2947, 1643, 1512, 1242, 1188, 1088, 1034; HRMS (ESI): Calcd for C₁₉H₂₀CINO₂ (MH⁺) 330.1261; Found : 330.1267. [α]_D²⁵ = – 97.6 (*c* 0.8, CH₂Cl₂). HPLC



analysis: 85:15 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 17.376 min, *t* (major) = 19.863 min].

(*R*)-(2-(4-Chlorophenyl)-1-(4-methoxyphenyl)-1,2,5,6tetrahydropyridin-3-yl)methanol (5i):

Colorless viscous liquid, (69 mg, 70% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.25–2.30 (m, 1H), 2.38–2.46 (m, 1H), 3.12–3.17 (m, 2H), 3.74 (s, 3H), 3.87 (d, *J* = 13.1 Hz, 1H), 3.95 (d, *J* = 12.8 Hz, 1H), 5.06 (s, 1H), 6.08 (t, *J* = 3.2 Hz, 1H), 6.75 (d, *J* = 9.1 Hz, 2H), 6.84 (d, *J* = 9.1 Hz, 2H), 7.05 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.71, 42.31, 55.38, 61.76, 64.78, 114.08 (2C), 121.09 (2C), 124.11, 127.99 (2C), 130.16 (2C), 133.02, 137.42, 137.60, 144.12, 154.02; IR (KBr)/cm⁻¹ 3418, 2916, 2847, 1651, 1597, 1594, 1242, 1188, 1095, 1026; HRMS (ESI): Calcd for C₁₉H₂₀ClNO₂ (MH⁺) 330.1261; Found : 330.1263. [α]_D²⁵ = – 143.2 (*c* 0.7, CH₂Cl₂). HPLC analysis: 86:14 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 20.054 min, *t* (major) = 23.154 min].

(S)-(2-(2-Bromophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5j)



Reddish viscous liquid, (65 mg, 58% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.30–2.35 (m, 2H), 3.14–3.19 (m, 1H), 3.23–3.30 (m, 2H), 3.52 (d, J = 13.9 Hz, 1H), 3.60 (d, J = 14.0 Hz, 1H), 3.76 (s, 3H), 5.55 (s, 1H), 5.91 (bs, 1H), 6.82 (d, J = 9.2 Hz, 2H), 6.90 (d, J = 9.1 Hz, 2H), 7.14–7.18 (m, 1H), 7.33–7.39 (m,

1H), 7.53–7.55 (m, 1H), 7.59–7.61 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 23.36, 45.13, 55.36, 59.75, 64.72, 114.04 (2C), 121.06 (2C), 124.97, 126.17, 127.03, 128.78, 130.19, 133.18, 137.67, 140.09, 144.35, 153.98; IR (KBr)/cm⁻¹ 3317, 3055, 2916, 2847, 1512, 1450, 1242, 1180, 1034; HRMS (ESI): Calcd for C₁₉H₂₀BrNO₂ (MH⁺) 374.0755; Found: 374.0759. [α]_D²⁵ = – 32.3 (*c* 0.6, CH₂Cl₂). HPLC analysis: 98:2 er [Daicel Chiralpak-IB, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 10.465 min, *t* (major) = 13.302 min].

(R)-(2-(3-Bromophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5k)



Yellow viscous liquid, (75 mg, 67% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.27-2.28 (m, 1H), 2.41-2.48 (m, 1H), 3.19-3.22 (m, 2H), 3.77 (s, 3H), 3.92 (d, J = 12.9 Hz, 1H), 4.01 (d, J = 12.8 Hz, 1H), 5.07 (s, 1H), 6.12 (t, J = 4.2 Hz)Hz, 1H), 6.79 (d, J = 9.2 Hz, 2H), 6.88 (d, J = 9.1 Hz, 2H), 7.05–7.12 (m, 2H), 7.34–7.37 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.44, 42.35, 55.40, 61.75, 64.69, 114.12 (2C), 120.86 (2C), 122.09, 124.34, 127.66, 129.40, 130.34, 131.49, 137.24, 141.57, 144.01,

153.98; IR (KBr)/cm⁻¹3302, 3055, 2916, 2839, 1566, 1512, 1458, 1242, 1180, 1034; HRMS (ESI): Calcd for $C_{19}H_{20}BrNO_2$ (MH⁺) 374.0755; Found: 374.0762. $[\alpha]_D^{25} = -113.3$ (c 1.5, CH₂Cl₂). HPLC analysis: 90:10 er [Daicel Chiralpak-IA, n-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), t (minor) = 17.692 min, t (major) = 19.870 min].

(*R*)-(2-(4-Bromophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5l):



Colorless viscous liquid, (77 mg, 69% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.25–2.30 (m, 1H), 2.38–2.46 (m, 1H), 3.13–3.16 (m, 2H), 3.74 (s, 3H), 3.87 (d, J = 12.0 Hz, 1H), 3.96 (d, J = 12.9 Hz, 1H), 5.04 (s, 1H), 6.08 (t, J = 4.2 Hz)Hz, 1H), 6.75 (d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 6.99 (d, J = 9.6 Hz, 2H), 6.99 (d

Hz, 2H), 7.33 (d, J = 9.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.70, 42.31, 55.37, 61.79, 64.70, 114.09 (2C), 121.05 (2C), 121.24, 124.07, 130.51 (2C), 130.91 (2C), 137.52, 137.94, 144.08, 154.01; IR (KBr)/cm⁻¹ 3418, 2916, 2908, 1659, 1504, 1242, 1188, 1026, 818; HRMS (ESI): Calcd for C₁₉H₂₀BrNO₂ (MH⁺) 374.0755; Found: 374.0757. $[\alpha]_D^{25} = -187.5$ (c 0.8, CH₂Cl₂). HPLC analysis: 92:8 er [Daicel Chiralpak-IA, n-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), t (minor) = 21.191 min, t (major) = 25.148 min].

(R)-(2-(3-Bromo-4-fluorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-



yl)methanol (5m):

Pale yellow viscous liquid, (83 mg, 71% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.26–2.31 (m, 1H), 2.37–2.45 (m, 1H), 3.09–3.17 (m, 2H), 3.75 (s, 3H),

3.86-3.89 (d, J = 12.3 Hz, 1H), 3.98 (d, J = 12.9 Hz, 1H), 5.04 (s, 1H), 6.10 (t, J = 3.0 Hz, 1H),

6.77 (d, J = 9.1 Hz, 2H), 6.84 (d, J = 9.2 Hz, 2H), 6.92–6.96 (m, 1H), 6.98–7.02 (m, 1H), 7.32– 7.34 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 24.56, 42.35, 55.40, 61.31, 64.64, 114.16 (2C), 121.18 (2C), 124.50, 129.45, 129.52, 133.41, 136.46, 137.22, 143.84, 154.21, 156.91, 159.36; IR (KBr)/cm⁻¹ 3279, 3047, 2914, 2847, 1558, 1504, 1242, 1180, 1034; HRMS (ESI): Calcd for C₁₉H₁₉BrFNO₂ (MH⁺) 392.0661; Found: 392.0667. [α]_D²⁵ = – 95.4 (*c* 1.2, CH₂Cl₂). HPLC analysis: 87:13 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 17.880 min, *t* (major) = 20.715 min].

(*R*)-3-(3-(Hydroxymethyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-2-yl)benzonitrile (5n):



Yellow viscous liquid, (71 mg, 74% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.29–2.38 (m, 1H), 2.40–2.45 (m, 1H), 3.07–3.21 (m, 2H), 3.74 (s, 3H), 3.82–3.85 (m, 1H), 3.98 (d, J = 13.0 Hz, 1H), 5.11 (s, 1H), 6.13 (t, J = 3.1Hz, 1H), 6.75 (d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 7.28–7.32 (m,

1H), 7.34–7.37 (m, 1H), 7.47–7.50 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.55, 42.70, 55.33, 61.53, 64.50, 111.65, 114.15 (2C), 118.85 121.11 (2C), 124.84, 128.62, 130.92, 132.02, 133.46, 136.75, 140.74, 143.70, 154.20; IR (KBr)/cm⁻¹ 3418, 2924, 2947, 2230, 1605, 1512, 1458, 1242, 1188, 1034; HRMS (ESI): Calcd for C₂₀H₂₀N₂O₂ (MH⁺) 321.1603; Found: 321.1609. [α]_D²⁵ = – 143.3 (*c* 0.8, CH₂Cl₂). HPLC analysis: 88:12 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 85/15), flow rate (0.5 mL/min), *t* (major) = 16.913 min, *t* (minor) = 21.912 min].

(*R*)-4-(3-(Hydroxymethyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-2-yl)benzonitrile (50)



Pale yellow viscous liquid, (74 mg, 78% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.28–2.34 (m, 1H), 2.38–2.47 (m, 1H), 3.08–3.17 (m, 2H), 3.74 (s, 3H), 3.84 (d, *J* = 12.3 Hz, 1H), 3.97 (d, *J* = 12.9 Hz, 1H), 5.12 (s, 1H), 6.12 (t, *J* = 3.1 Hz, 1H), 6.75 (d, *J* = 9.1 Hz, 2H), 6.82 (d, *J* = 9.1 Hz, 2H), 7.25 (d, *J*

= 8.3 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.62, 42.77, 55.28, 61.88, 64.42, 110.77, 114.09 (2C), 118.70, 121.02 (2C), 124.58, 129.36 (2C), 131.55 (2C), 136.78, 143.73, 144.74, 154.13; IR (KBr)/cm⁻¹ 3418, 2924, 2862, 2230, 1659, 1512, 1458, 1250, 1188, 1095, 1034; HRMS (ESI): Calcd for C₂₀H₂₀N₂O₂ (MH⁺) 321.1603; Found: 321.1605. [α]_D²⁵ = -

182.4 (*c* 1.5, CH₂Cl₂). HPLC analysis: 90:10 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 80/20), flow rate (0.5 mL/min), *t* (minor) = 16.974 min, *t* (major) = 18.771 min].

(R)-(2-(3,4-Dichlorophenyl)-1-(4-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl) methanol



(**5p**)

Orange liquid, (76 mg, 70% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.25–2.30 (m, 1H), 2.36–2.44 (m, 1H), 3.08–3.17 (m, 2H), 3.73 (s, 3H), 3.85 (d, J = 12.3 Hz, 1H), 3.97 (d, J = 12.9 Hz, 1H), 5.03 (s, 1H), 6.09 (t, J = 3.1 Hz, 1H), 6.75 (d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 6.93 (dd, J = 8.2 Hz, J = 2.0 Hz, 1H), 7.23–7.25 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.56, 42.53, 55.36, 61.33, 61.51, 114.19 (2C), 121.04 (2C), 124.49, 128.29, 129.70, 130.39, 131.13, 131.86, 137.03, 139.51, 143.81, 154.18; IR (KBr)/cm⁻¹ 3410, 3055, 2916, 2839, 1605, 1512, 1458, 1396, 1242, 1188, 1034; HRMS (ESI): Calcd for C₁₉H₁₉Cl₂NO₂ (MH⁺) 364.0871; Found: 364.0876. [α]_D²⁵ = – 193 (*c* 1.3, CH₂Cl₂). HPLC analysis: 93:7 er [Daicel



Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 17.848 min, *t* (major) = 21.804 min].

(*R*)-(1-(4-Methoxyphenyl)-2-phenyl-1,2,5,6-tetrahydropyridin-3yl)methanol (5q):

Yellow viscous oil, (51 mg, 58% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.23–2.28 (m, 1H), 2.40–2.45 (m, 1H), 3.17–3.21 (m, 2H), 3.73 (s, 3H), 3.93 (m, 2H), 5.09 (s, 1H), 6.07 (bs, 1H), 6.75 (d, J = 9.1 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 7.12–7.15 (m, 2H), 7.20–7.22 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 24.54, 42.22, 55.39, 62.31, 64.94, 114.03 (2C), 120.73 (2C), 123.79, 127.27, 127.88 (2C), 128.87 (2C), 137.95, 139.10, 144.41, 153.73; IR (KBr)/cm⁻¹ 3394, 2924, 2854, 1736, 1512, 1458, 1381, 1242, 1180, 1034, 875; HRMS (ESI): Calcd for C₁₉H₂₁NO₂ (MH⁺) 296.1650; Found: 296.1658. [α]_D²⁵ = – 140.5 (*c* 0.5, CH₂Cl₂). HPLC analysis: 85:15 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 88/12), flow rate (0.5 mL/min), *t* (minor) = 13.505 min, *t* (major) = 15.262 min].

(S)-(1-(4-Methoxyphenyl)-2-phenyl-1,2,5,6-tetrahydropyridin-3-yl)methanol (*ent*-5q):



 $\begin{bmatrix} \alpha \end{bmatrix}_{D}^{25} = + 42.3 \ (c \ 0.1, \ CH_2Cl_2). \ HPLC \ analysis: 18:82 \ er \ [Daicel Chiralpak-IA,$ $n-hexane/2-propanol = 88/12), \ flow \ rate \ (0.5 \ mL/min), \ t \ (major) = 13.397 \ min,$ $t \ (minor) = 15.273 \ min].$

(S)-(1-(4-Methoxyphenyl)-2-(pyridin-2-yl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5r):



Dark red viscous liquid, (56 mg, 63% yield), ¹H NMR ¹H NMR (400 MHz, CDCl₃) δ 2.33–2.37 (bs, 2H), 3.19–3.25 (m, 1H), 3.34-3.40 (m, 1H), 3.74 (s, 3H), 4.07 (d, J = 12.5 Hz, 1H), 4.14 (d, J = 12.4 Hz, 1H), 5.27 (s, 1H), 5.99 (t, J = 3.9 Hz, 1H), 6.79-6.80 (m, 2H), 6.82-6.83 (m, 2H), 7.16–7.19 (m, 1H), 7.33

(d, J = 7.8 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 8.50 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 23.81, 43.93, 55.49, 63.71, 65.88, 114.48 (2C), 117.45 (2C), 120.86, 122.50, 124.11, 124.93, 136.86, 137.42, 148.07, 159.26, 161.77; IR (KBr)/cm⁻¹ 3294, 3055, 2924, 2839, 1466, 1242, 1034; HRMS (ESI): Calcd for C₁₈H₂₀N₂O₂ (MH⁺) 297.1603; Found: 297.1608. [α]_D²⁵ = - 111.5 (*c* 0.8, CH₂Cl₂). HPLC analysis: 91:9 er [Daicel Chiralpak-IB, *n*-hexane/2-propanol = 85/15), flow rate (0.5 mL/min), *t* (minor) = 22.747 min, *t* (major) = 28.847 min].

(*R*)-(1-(4-Methoxyphenyl)-2-(pyridin-3-yl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5s)



Red viscous liquid, (64 mg, 72% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.27–2.32 (m, 1H), 2.40–2.50 (m, 1H), 3.09–3.17 (m, 2H), 3.73 (s, 3H), 3.87 (d, J = 13.0 Hz, 1H), 3.99 (d, J = 12.9 Hz, 1H), 5.12 (s, 1H), 6.13 (s, 1H), 6.75 (d, J = 9.0 Hz, 2H), 6.84 (d, J = 9.1 Hz, 2H), 7.13–7.15 (m, 1H), 7.42–7.44 (m, 1H),

8.32 (s, 1H), 8.41 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 24.70, 42.52, 55.37, 60.18, 64.41, 141.18 (2C), 121.29 (2C), 123.07, 124.44, 135.00, 136.63, 136.92, 143.86, 148.23, 149.69, 154.24; IR (KBr)/cm⁻¹ 3410, 2924, 2862, 1651, 1582, 1512, 1242, 1034; HRMS (ESI): Calcd for C₁₈H₂₀N₂O₂ (MH⁺) 297.1603; Found: 297.1605. [α]_D²⁵ = -103 (*c* 0.4, CH₂Cl₂). HPLC analysis: 81:19 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 80/20), flow rate (1.0 mL/min), *t* (minor) = 19.082 min, *t* (major) = 22.508 min].

(R)-(1-(4-Methoxyphenyl)-2-(pyridin-4-yl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5t)



Yellow viscous liquid, (67 mg, 76% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.26–2.31 (m, 1H), 2.39–2.47 (m, 1H), 3.08–3.22 (m, 2H), 3.73 (s, 3H), 3.87 (d, J = 12.7 Hz, 1H), 3.98 (d, J = 12.8 Hz, 1H), 5.08 (s, 1H), 6.12 (t, J = 3.2 Hz, 1H), 6.74 (d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 7.05 (d, J = 6.0 Hz, 2H), 8.41

(d, J = 5.9 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.60, 42.79, 55.38, 61.26, 64.38, 114.17 (2C),

115.35, 118.22, 120.82 (2C), 123.89, 124.57, 136.73, 143.87, 148.52, 149.08, 154.08; IR (KBr)/cm⁻¹ 3711, 3040, 2916, 2847, 1512, 1458, 1260, 1188; HRMS (ESI): Calcd for $C_{18}H_{20}N_2O_2$ (MH⁺) 297.1603; Found: 297.1611. [α]_D²⁵ = - 105.9 (*c* 0.7, CH₂Cl₂). HPLC analysis: 96:4 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 80/20), flow rate (1.0 mL/min), *t* (minor) = 20.044 min, *t* (major) = 24.477 min].

(S)-(1-(4-Methoxyphenyl)-2-(thiophen-2-yl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5u)



Reddish viscous oil, (48 mg, 53% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.24–2.29 (m, 1H), 2.43–2.52 (m, 1H), 3.21–3.24 (m, 2H), 3.75 (s, 3H), 4.02–4.09 (m, 2H), 5.41 (s, 1H), 6.03–6.05 (m, 1H), 6.66–6.68 (m, 1H), 6.78 (d, J = 9.2 Hz, 2H), 6.83–6.84 (m, 1H), 6.87 (d, J = 9.2 Hz, 2H), 7.12–7.13 (m, 1H); ¹³C

NMR (75 MHz, CDCl₃) δ 24.98, 41.06, 55.41, 57.89, 64.97, 114.13 (2C), 120.69 (2C), 123.85, 124.81, 126.12, 126.64, 138.29, 141.57, 144.02, 153.97; IR (KBr)/cm⁻¹ 3493, 2924, 2854, 1651, 1512, 1242, 1034; HRMS (ESI): Calcd for C₁₇H₁₉NO₂S (MH⁺) 302.1214; Found: 302.1219. [α]_D²⁵ = - 123 (*c* 0.2, CH₂Cl₂). HPLC analysis: 86:14 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 90/10), flow rate (0.5 mL/min), *t* (minor) = 30.484 min, *t* (major) = 36.166 min].

(*S*)-(1-(4-Methoxyphenyl)-2-(5-nitrofuran-2-yl)-1,2,5,6-tetrahydropyridin-3-yl)methanol (5v)



Dark red viscous liquid, (62 mg, 63% yield), ¹H NMR (400 MHz, CDCl₃) δ 2.28–2.35 (m, 2H), 3.22–3.25 (m, 2H), 3.64 (s, 2H), 3.77 (s, 3H), 4.11 (s, 1H), 5.86 (bs, 1H), 6.85 (d, *J* = 9.0 Hz, 2H), 6.98 (m, 2H), 7.27–7.30 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 25.03, 41.22, 55.48, 57.96, 65.05,

114.22 (2C), 120.89 (2C), 123.91, 124.84, 126.16, 126.63, 138.40, 141.83, 144.13, 154.04; IR (KBr)/cm⁻¹ 3420, 2924, 2848, 1512, 1458, 1404, 1250, 1188; HRMS (ESI): Calcd for $C_{17}H_{18}N_2O_5$ (MH⁺) 331.1294; Found: 331.1298. [α]_D²⁵ = - 146 (*c* 0.4, CH₂Cl₂). HPLC analysis: 86:14 er [Daicel Chiralpak-IA, *n*-hexane/2-propanol = 85/15), flow rate (0.5 mL/min), *t* (minor) = 25.996 min, *t* (major) = 30.493 min].

(4a*R*,10b*S*)-1-(4-Methoxyphenyl)-1,3,4,4a,5,10b-hexahydro-2*H*-chromeno[4,3-*b*]pyridine (6)



To a stirred solution of compound **5j** (160 mg, 0.43 mmol) in dry EtOH (4 mL) was added 10% Pd/C (10 wt %) and purged with H₂ and stirred under H₂ at room temperature for 4 hrs. Reaction mixture was filtered through celite and washed with ethanol. Solvent was evaporated under vacuo and crude material was used

for further oxidation without purification at this stage. This crude material was taken in DMF (3.0 mL) and added Pd(OAc)₂ (18 mg, 20 mol%) and KO'Bu (94 mg, 0.42 mmol) and PPh₃ (44 mg, 0.4 equivalents) and degassed the reaction mixture with nitrogen for 20 minutes. This reaction mixture was heated at 110 °C for 4 hrs and monitored by TLC. The reaction was quenched with saturated NaHCO₃ solution (5.0 mL) and extracted with EtOAc (2 × 8 mL). The combined organic layer was washed with brine and dried over Na₂SO₄ and concentrated under reduced pressure to give crude mass which was purified by silica gel column chromatography by using hexane:EtOAc, gave **6** (62 mg, 61% yield) as colorless viscous liquid. ¹H NMR (400 MHz, CDCl₃) δ 1.47–1.59 (m, 1H), 1.84–1.87 (m, 2H), 2.03–2.07 (m, 1H), 2.77 (m, 1H), 3.29–3.40 (m, 3H), 3.66 (s, 3H), 4.31 (d, *J* = 3.9 Hz, 1H), 6.63 (d, *J* = 9.1 Hz, 2H), 6.94–7.00 (m, 3H), 7.08 (m, 1H), 7.13–7.16 (m, 1H), 7.52–7.54 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 25.85, 27.62, 47.45, 55.15, 58.37, 61.89, 64.56, 113.65 (2C), 125.39 (2C), 127.11, 127.80, 128.61 (2C), 129.95 (2C), 133.70 (2C); IR (KBr)/cm⁻¹ 2932, 1597, 1298, 1180, 1034; HRMS (ESI): Calcd for C₁₉H₂₁NO₂ (MH⁺) 296.1650; Found: 296.1655. [α]_D²⁵ = -31.7 (*c* 0.4, CH₂Cl₂).

(4a*R*,10b*S*)-1,3,4,4a,5,10b-Hexahydro-2*H*-chromeno[4,3-*b*]pyridine (7)



To a stirred solution of ceric ammonium nitrate (CAN) (441 mg, 0.8 mmol) in distilled H_2O (2.0 mL) at 0 °C was added compound **6** (95 mg, 0.32 mmol) in CH₃CN (3.0 mL) dropwise for 10 minutes. This reaction mixture was further stirred at rt for 1 hr and monitored by TLC. Once, compound **6** was consumed

completely, reaction was quenched with saturated NaHCO₃ (5.0 mL) and extracted with EtOAc (3 × 5 mL). The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure after filtration. The crude mas was purified through a small pad of silica gel column using hexane:acetone as eluting solvent, afforded **7** (46 mg, 75% yield) as colorless viscous liquid. ¹H NMR (400 MHz, CDCl₃) δ 1.41–1.52 (m, 2H), 2.02–2.07 (m, 2H), 2.62 (s, 1H), 2.76–2.83 (m, 1H), 3.16–3.20 (m, 1H), 3.27–3.38 (m, 2H), 3.58–3.65 (m, 1H), 4.07 (d, *J* = 3.8 Hz, 1H), 7.18–7.22 (m, 1H), 7.28–7.30 (m, 1H), 7.35 (dd, *J* = 7.9 Hz, *J* = 1.3 Hz, 1H), 7.61 (dd, *J* = 7.7 Hz, *J* =

1.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 26.31, 28.04, 48.15, 58.59, 64.95, 70.16, 125.23, 128.05, 128.56, 130.85, 132.36, 156.15; IR (KBr)/cm⁻¹ 3433, 2932, 1597, 1350, 1103; HRMS (ESI): Calcd for C₁₂H₁₅NO (MH⁺) 190.1232; Found: 190.1235 [α]_D²⁵ = - 29.2 (*c* 0.1, CH₂Cl₂).

((1*S*,2*R*,6*S*)-3-(4-Methoxyphenyl)-2-(4-nitrophenyl)-7-oxa-3-azabicyclo[4.1.0] heptan-1-yl)methanol (10)



To a stirred solution of compound **5c** (64 mg, 0.19 mmol) in CH₂Cl₂ (2.0 mL) at 0 °C was added *m*-CPBA (56 mg, 0.38 mmol) predissolved in CH₂Cl₂ (1.0 mL) through syringe. This reaction mixture was further stirred for 3 hr at the same temperature and monitored by TLC. Once, compound

5c was consumed, reaction was stirred with NaHCO₃ solution (3.0 mL, 10 mol % sol.) for 10 minutes. This reaction mixture was extracted with CH₂Cl₂ (5.0 mL) and combined organic layer was washed with brine solution and dried over Na₂SO₄. The crude mass after concentrated under vacuo was purified through column chromatography by unsing hexane/EtOAc as eluting solvents, which afford compound **10** (50 mg, 75% yield) as a colorless viscous liquid. ¹H NMR (400 MHz, CDCl₃) δ 2.44 (d, *J* = 4.2 Hz, 1H), 3.23 (d, *J* = 11.6 Hz, 1H), 3.44 (d, *J* = 11.7 Hz, 1H), 3.69–3.78 (m, 6H), 4.63–4.70 (m, 1H), 5.02 (s, 1H), 5.40 (s, 1H), 6.68 (d, *J* = 9.4 Hz, 2H), 7.03 (d, *J* = 8.9 Hz, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.84–7.95 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 25.17, 32.70, 43.34, 55.70, 58.15, 69.66, 72.58, 114.92 (2C), 121.97 (2C), 123.75 (2C), 130.25 (2C), 137.58, 144.45, 147.76, 155.05; IR (KBr)/cm⁻¹ 3433, 2916, 2854, 1713, 1574, 1381, 1257, 1080, 756; HRMS (ESI): Calcd for C₁₉H₂₀N₂O₅ (MH⁺) 357.1450; Found: 357.1455. [α]_D²⁵ = + 43.8 (*c* 0.2, CH₂Cl₂).

(2*R*,3*S*,4*S*)-3-(Hydroxymethyl)-1-(4-methoxyphenyl)-2-(4-nitrophenyl) piperidine-3,4-diol (11)



To a stirred solution of compound **5c** (60 mg, 0.18 mmol) in acetone (2.5 mL) and H₂O (0.5 mL) was added 4-Methylmorpholine *N*-oxide (NMO) (32 mg, 0.27 mmol) and OsO₄ (20 mol %, 1.76 mL, 0.02 M solution in *tert*-BuOH). This reaction mixture was stirred at room temperature for 12 hrs and monitored by TLC. The reaction mixture was evaporated under reduced

pressure, once **6c** was completely consumed. The resulting mass was stirred with EtOAc (10 ml) and saturated NaHCO₃ (8.0 mL) for 10 minutes. Organic layer was separated and the aqueous

layer was again extracted with EtOAc (2 × 10 mL). The combined organic layer was dried over Na₂SO₄ and evaporated under reduced pressure after filtration. The resulting mass was purified through column chromatography using hexane/EtOAc as eluting solvents, which afforded **11** (42 mg, 65 % yield). ¹H NMR (400 MHz, CDCl₃) δ 1.94–1.98 (m, 1H), 2.27–2.35 (m, 1H),3.11–3.21 (m, 2H), 3.56 (d, *J* = 11.6 Hz, 1H), 3.67 (s, 3H), 3.73 (bs, 1H), 3.75–3.79 (m, 1H), 4.19 (t, *J* = 3.7 Hz, 1H), 4.65 (s, 1H), 6.65 (d, *J* = 9.0 Hz, 2H), 6.87 (d, *J* = 9.0 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 7.99 (d, *J* = 8.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 29.44, 51.47, 55.22, 63.94, 67.55, 69.20, 73.56, 114.14 (2C), 122.67 (2C), 125.11 (2C), 130.69 (2C), 144.11, 145.21, 146.74, 156.02; IR (KBr)/cm⁻¹ 3441, 2939, 1597, 1520, 1350, 1250, 1103; HRMS (ESI): Calcd for C₁₉H₂₂N₂O₆ (MH⁺) 375.1556; Found: 375.1560. [α]_D²⁵ = – 61.5 (*c* 0.15, CH₂Cl₂).

(R)-1-(4-Methoxyphenyl)-2-phenyl-1,2,5,6-tetra-hydropyridine-3-carboxylic acid (12)



To a stirred solution of compound **5q** (81 mg, 0.2 mmol) in acetonitrile (1.5 mL) and H₂O (0.5 mL) at 0 °C, was added slowly a freshly prepared solution (1.5 mL) of oxidizing agents [*prepared through reported procedure*,²⁶ (2.3 mg of CrO₃ and 1.14 grams of H₅IO₆), in H₂O (12.0 mL)] over a period of 30

minutes. The combined mixture was further stirred for additional 1 hr at rt and monitored by the TLC. The reaction was extracted with CH₂Cl₂ (2 × 10 mL), once **5q** was over. The combined organic fractions are passed through a small pad of Na₂SO₄ and concentrated under reduced pressure. The crude mass was purified through preparative TLC technique by eluting with CH₂Cl₂, to afford **12** (57 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ 2.38 (m, 1H), 2.60–2.73 (m, 1H), 3.20–3.28 (m, 1H), 3.30–3.35 (m, 1H), 3.76 (s, 3H), 5.23 (s, 1H), 6.12 (s, 1H), 6.76 (d, *J* = 9.1 Hz, 2H), 6.89 (d, *J* = 9.1 Hz, 2H), 7.01 (dd, *J* = 8.0, 1.4 Hz, 2H), 7.18–7.26 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 29.65, 44.12, 55.54, 63.54, 114.61 (2C), 123.49 (2C), 127.98, 128.67, 129.16, 130.46, 131.40, 131.74, 133.31, 134.18, 141.74, 160.01, 171.00; IR (KBr)/cm⁻¹ 3441-3061 (br), 2939, 1690, 1582, 1512, 1126; HRMS (ESI): Calcd for C₁₉H₁₉NO₃ (MH⁺) 310.1443; Found: 310.1439. [α]_D²⁵ = – 127.4 (*c* 0.25, CH₂Cl₂).

(2S,3R)-1-(4-Methoxyphenyl)-2-phenylpiperidine-3-carboxylic acid (14)



To a stirred solution of compound *ent*-**5q** (96 mg, 0.32 mmol) in dry EtOH (4 mL) was added 10% Pd/C (10 wt %) and purged with H_2 and stirred under H_2 at room temperature for 4 hrs. Reaction mixture was filtered through celite and

washed with ethanol. Solvent was evaporated under vacuo and crude material was used for further oxidation without purification at this stage. The oxidation of crude saturated *syn*-alcohol to corresponding acid was carried out by following the previous procedure, similar to compound **12**, to afford **14** (66 mg, 66% yield) after two steps. ¹H NMR (400 MHz, CDCl₃) δ 1.86–1.94 (m, 1H), 2.01–2.08 (m, 2H), 3.25–3.30 (m, 2H), 3.43–3.46 (m, 2H), 3.66 (s, 3H), 3.92 (d, *J* = 3.9 Hz, 1H), 6.63 (d, *J* = 9.1 Hz, 2H), 7.04 (d, *J* = 8.5 Hz, 2H), 7.15 (m, 3H), 7.38–7.42 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 22.68, 27.19, 29.68, 42.65, 55.24, 64.90, 113.85 (2C), 124.83, 127.32, 127.90 (2C), 128.28, 128.73, 131.23, 132.44, 135.92, 141.29, 170.16; IR (KBr)/cm⁻¹ 3433–3063 (br), 2939, 1690, 1589, 1173, 1034; HRMS (ESI): Calcd for C₁₉H₂₁NO₃ (MH⁺) 312.1599; Found: 312.1592 [α]_D²⁵ = + 49.4 (*c* 0.1, CH₂Cl₂).

(2S,3R)-1-(4-Methoxyphenyl)-2-phenylpiperidin-3-yl)methanol (16)



Compound **5q** (140 mg, 0.32 mmol), was reduced by following previous procedure and purified through column chromatography to afford **16** as colorless viscous liquid with 90% yield (126 mg). ¹H NMR (400 MHz, CDCl₃) δ 1.62–1.69 (m, 2H), 1.83 (d, J = 6.4 Hz, 2H), 2.61–2.70 (m, 2H), 3.00–3.09

(m, 2H), 3.50–3.55 (m, 2H), 3.75 (s, 3H), 3.76–3.83 (m, 1H), 6.56 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 7.16–7.22 (m, 3H), 7.29 (t, J = 6.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 25.51, 27.42, 45.96, 55.18, 56.60, 65.27, 67.46, 113.66 (2C), 125.11, 126.72 ,128.02 (2C) ,128.47 (2C), 139.24 , 142.13, 146.05, 155.21; HRMS (ESI): Calcd for C₁₉H₂₃NO₂ (MH⁺) 298.1808, Found: 298.1813. [α]_D²⁵ = -56.3 (c 0.1, CH₂Cl₂).

2-Methoxy-N-(((2*S*,3*S*)-1-(4-methoxyphenyl)-2-phenylpiperidin-3-yl)methyl) aniline (19)



To a stirred solution of **20** (90 mg, 0.3 mmol) in dry CH_2Cl_2 (2.0 mL) at rt was added Et_3N (168 µL, 1.2 mmol) and TsCl (69 mg, 0.36 mmol) in dry CH_2Cl_2 (1.5 mL) by syringe. The resulting mixture was further stirred for 6 hrs at the same temperature and monitored by TLC. The reaction was quenched with saturated NaHCO₃ (3.0 mL) and extracted with CH_2Cl_2 (2 ×

5 mL). The combined organic layer was dried over Na_2SO_4 and concentrated in reduced pressure to give crude product, which was used further without isolation. The crude mass was taken in dry EtOH (3 mL) and added *o*-anisidine **18** (74 mg, 0.6 mmol) and further refluxed for additional 4 hrs. Once the reaction is over by TLC, EtOH was evaporated under reduced pressure and resulting residue was purified by column chromatography to afforded **19** (83 mg, 68% yield) as colorless viscous liquid. ¹H NMR (400 MHz, CDCl₃) δ 1.58–1.75 (m, 4H), 2.10–2.13 (m, 1H), 2.93–3.00 (m, 1H), 3.12–3.16 (m, 1H), 3.49–3.57 (m, 2H), 3.78 (s, 3H), 3.86 (s, 3H), 5.04 (d, *J* = 3.6, 1H), 6.47–6.49 (m, 1H), 6.56–6.60 (m, 1H), 6.72–6.76 (m, 2H), 6.78–6.81 (m, 2H), 6.84 (H₂ $_{0}$) 9.2, 2H), 6.91(d, *J* = 9.2 Hz, 2H), 6.99–7.03 (m, 1H), 7.14 (d, *J* = 7.6 Hz, 1H); ¹⁸C NNR (75 MHz, CDCl₃) δ 24.28, 24.51, 31.47, 42.12, 46.55, 55.39, 55.75, 56.69, 110.37, 113.60, 115.94, 117.00, 118.46, 120.11, 121.03, 127.61 (2C), 128.07, 136.08, 144881, 145.62, 147.28, 151.61; IR (KBr)/cm⁻¹ 3393, 2932, 2831, 1598, 1512, 1366, 1180, 1034; Calcd for C₂₆H₃₀N₂O₂ (MH⁺) 403.2385; Found: 403.2389. [α]_D²⁵ = – 54.6 (*c* 0.15, CH₂Cl₂).





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	15.471	13083924	49.02	357333
2	PDA 250.0 nm	23.693	13609532	50.98	270013



Processed Channel Descr.: PDA 250.0 nm

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	15.224	321042	3.01	9570
2	PDA 250.0 nm	22.808	10327670	96.99	185851





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	29.113	21841808	52.66	352775
2	PDA 250.0 nm	32.690	19634952	47.34	295236





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 7896; Processing Method: 3 NITRO CHIRAL THP

Processed	Channel	Descr.: F	PDA 250).0 nm

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	29.538	4888269	6.31	74907
2	PDA 250.0 nm	33.207	72569640	93.69	1023344





Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 7863; Processing Method: 4 NITRO RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	18.634	67961973	52.87	1684220
2	PDA 250.0 nm	23.939	60575125	47.13	1200481





Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 7865; Processing Method: 4 NITRO CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.932	1239998	3.01	29304
2	PDA 250.0 nm	22.037	39964344	96.99	907207







	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	12.599	6555802	53.51	224136
2	PDA 250.0 nm	16.538	5695813	46.49	158347





Processed Channel	Descr.: PDA 250.0 nm	

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	11.835	499839	2.48	21526
2	PDA 250.0 nm	14.871	19661013	97.52	647097





FIOLESSEU GHAIHEI DESCH. FDA 230.0 HH	Processed	Channel	Descr.:	PDA	250.0) nm
---------------------------------------	-----------	---------	---------	-----	-------	------

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.480	15290807	18.72	368440
2	PDA 250.0 nm	20.078	66384896	81.28	1456721







Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 7922; Processing Method: 4F CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	18.826	11418942	17.10	296796
2	PDA 250.0 nm	20.510	55370205	82.90	1280260







		n	m		
	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	8.160	6240350	48.08	331077
2	PDA 250.0 nm	11.365	6739902	<mark>51.92</mark>	258215
	id Ai			12	8)



Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8388; Processing Method: 2 CHLRO CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	8.278	403096	2.82	22153
2	PDA 250.0 nm	11.601	13905371	97.18	512154





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.376	6365899	14.72	148767
2	PDA 250.0 nm	19.863	36871615	85.28	804214





RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	19.954	53061234	48.36	1154391
2	PDA 250.0 nm	23.139	56668222	51.64	1048413







	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	20.054	11970301	13.96	244304
2	PDA 250.0 nm	23.154	73804689	<mark>86.04</mark>	1421144





____ Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 8314; Processing Method: 2 RACEMIC THP

Processed Channel	Descr.:	PDA	250.0	nm
-------------------	---------	-----	-------	----

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	9.740	31666174	49.12	1008518
2	PDA 250.0 nm	12.246	32794376	50.88	1046111





Processed Channel Descr.: PDA 250.0 nm

THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	10.465	768403	2.49	21397
2	PDA 250.0 nm	13.302	30106963	97.51	843809





RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.657	64363439	52.54	1547168
2	PDA 250.0 nm	19.879	58147067	47.46	1391268





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 7990; Processing Method: 3 BROMO CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.692	14880585	9.84	350042
2	PDA 250.0 nm	19.870	136420501	90.16	3160055





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	21.191	13203192	7.81	280793
2	PDA 250.0 nm	25.148	155825705	92.19	3192249





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8056; Processing Method: 3BR 4F RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.869	64069717	55.00	1430273
2	PDA 250.0 nm	20.921	52410682	45.00	1314742





Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 8045; Processing Method: 3 BR 4 F CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.880	9838697	12.52	222367
2	PDA 250.0 nm	20.715	68715444	87.48	1333644





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	16.913	98406714	88.09	2907512
2	PDA 250.0 nm	21.912	13300190	11.91	267504





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	16.032	17238920	36.88	473417
2	PDA 250.0 nm	17.607	29507228	63.12	521904





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	16.974	3333045	9.80	91005
2	PDA 250.0 nm	18.771	30667437	90.20	581946





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	17.848	4566887	7.48	102766
2	PDA 250.0 nm	21.804	56495197	92.52	1144218









	Retention Time	Area	% Area	Height
1	13.505	3275267	15.03	109433
2	15.262	18522896	84.97	583829



Chiral ent-5q







Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8341; Processing Method: 2 PY RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	23.191	48295556	42.30	868004
2	PDA 250.0 nm	29.197	65883976	57.70	1014510







	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	22.747	4125038	9.17	67417
2	PDA 250.0 nm	28.847	40870051	90.83	562472





	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	19.082	4513431	18.56	109892
2	PDA 250.0 nm	22.508	19809305	81.44	418745





	Processed Channel Descr.	RT	Area	% Area	Height			
1	FDA 250.0 nm	20.044	296556	4.24	5200			
2	PDA 250.0 nm	24.477	6694887	95.76	107102			





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8079; Processing Method: THIOPHENE 2 RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	29.298	72536719	50.02	959798
2	PDA 250.0 nm	34.641	72465682	<mark>4</mark> 9.98	902550





Channel: 2998; Processed Channel: PDA 250.0 nm; Result ld: 8074; Processing Method: THIOPHENE 2 CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	30.484	11179571	13.60	138282
2	PDA 250.0 nm	36.166	71039168	86.40	774084





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8334; Processing Method: 5 NO2 FURYL RACEMIC THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	26.053	27305834	56.77	454071
2	PDA 250.0 nm	30.897	20793365	43.23	350452





Channel: 2998; Processed Channel: PDA 250.0 nm; Result Id: 8336; Processing Method: 5 NITRO FURYL CHIRAL THP

	Processed Channel Descr.	RT	Area	% Area	Height
1	PDA 250.0 nm	25.996	7216186	14.25	112766
2	PDA 250.0 nm	30.493	43430027	85.75	644159















S69

